Compare 8 RTSM and IRT systems across randomization, trial supply, build speed, integrations, compliance evidence and track record. None of the eight vendors publishes prices, so plan on a quote for each study. Use the sourced feature notes to discuss your protocol and supply requirements with vendors.
Best forSponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.
Updated Nov 12, 20268 tools compared
RTSM / IRT
What are RTSM and IRT?
RTSM means randomization and trial supply management. It assigns participants to treatment groups and coordinates the study-drug supply. IRT, or interactive response technology, is a related term commonly used for the systems that run these workflows.
See documented feature support at a glance. Select a symbol for the explanation and source. Double checks indicate documented extra capabilities; unknown does not mean unavailable.
Products are not ranked. Table order is chosen for each guide and does not indicate a recommendation.
Columns 6 of 6
Feature 1 of 6
Select a symbol to read its evidence and source. Scroll sideways for all features.
Documented feature support for each product. Symbols describe individual features, not overall product ratings.
Named methods include variable blocks and minimization with blinding protection.
Extended support means: Named allocation methods include minimization or dynamic allocation.
4G names stratification, cohort-specific logic, variable blocks and minimization, with versioned logic that protects blinding and handles re-randomization.
Predictive resupply, scenario modeling and direct-to-patient shipping are stated.
Extended support means: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Prancer handles dispensing and resupply with buffer-to-predictive forecasting and 4C Supply scenario modeling; direct-to-patient shipping was added in April 2020 (4G blog).
A build timeline and changes protecting study progress are stated; uninterrupted live use is not explicit.
Supported means: Study setup or post-go-live study changes are described.
4G says its NLP-based build takes under four weeks, with specification sign-off to go-live in as little as 13 calendar days, and changes made without impacting study progress.
Connections to trial systems establish base support; a public API reference was not found.
Supported means: Integration or data exchange with another system or application is described.
4G documents connections to EDC, CTMS, depot and logistics systems and data warehouses, but has no EDC or eCOA of its own and we found no public API reference.
Resupply and SupplyWise forecasting combine with documented direct-to-patient workflows.
Extended support means: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
IXRS 3 documents resupply strategy, expiry and depot management, Almac's SupplyWise integrates demand forecasting with the IRT, and an Almac datasheet (Clinical Leader, August 2025) describes direct-to-patient workflows.
EDC/CTMS connectors are documented with REST and SOAP integrations.
Extended support means: Integration with a clinical-trial application plus an API for integration are both stated.
Almac lists pre-built connectors and REST, SOAP and secure file integrations with EDC, CTMS, clinical supplies and central labs, but has no EDC or eCOA of its own.
The Part 11 statement is limited to IXRS University training; ISO/SOC evidence was not found.
Supported means: Relevant trial compliance or security controls are stated, with their scope identified.
Almac states its IXRS University training module is validated and 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation for Clinical Technologies.
Product-specific trial and patient figures are reported across a stated country count.
Extended support means: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Almac's media kit reports 2,000 clinical trials and over 2 million patients on IXRS, in more than 85 countries (undated kit).
Adaptive protocol support establishes base support; allocation methods are not named.
Supported means: Randomization or blinding workflows are stated.
Endpoint cites complex protocols, dosing strategies, adaptive designs and patient rollover, but its product pages do not name specific allocation methods.
API-based integrations connect RTSM with EDC, eCOA, eConsent and CTMS.
Extended support means: Integration with a clinical-trial application plus an API for integration are both stated.
Endpoint describes pre-built, API-based integrations with EDC, eCOA, eConsent and CTMS, but names no specific systems and has no EDC or eCOA of its own.
Product-specific study and patient adoption is reported across a stated country count.
Extended support means: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Endpoint reports 2,000+ studies, 1M+ patients and 90+ countries.
Named methods include permuted blocks and dynamic allocation with stratification.
Extended support means: Named allocation methods include minimization or dynamic allocation.
A Medidata fact sheet lists pre-validated permuted block and dynamic allocation, stratification, cohort management, titration and a randomization simulator (fact sheet dated May 2019).
Predictive supply schemes and forecasting are documented alongside direct-to-patient shipments.
Extended support means: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
The current fact sheet documents buffer and predictive supply schemes, forecasting that simulates future patient needs, direct-to-patient shipments and drug pooling across studies.
A build timeline and live amendments are stated, but little-to-no downtime permits some interruption.
Supported means: Study setup or post-go-live study changes are described.
Medidata states a 2-3 week study build, and Edit Live Design allows post-go-live changes for protocol amendments (the 2024 fact sheet adds 'little to no downtime').
A certificate and audit are listed, but public document access is not established; trial statements require customer login.
Supported means: Relevant trial compliance or security controls are stated, with their scope identified.
Medidata lists an ISO 27001:2022 certificate and a SOC 2+ Type II audit, and says its position statements cover 21 CFR Part 11 and EU Annex 11 (the statements sit behind a customer login).
Product-specific monthly patient usage is reported alongside a stated country count.
Extended support means: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
The RTSM page cites 124 countries supported and about 16,000 patients a month.
Direct-to-patient dispensing combines with a Forecasting and Planning module.
Extended support means: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Signant documents direct-to-patient dispensing, cross-study pooling, shelf-life optimization and a Forecasting and Planning module in SmartSignals Supplies.
The timeline ends at UAT; amendment impact assessment does not establish uninterrupted live changes.
Supported means: Study setup or post-go-live study changes are described.
Signant states new builds in as little as three weeks from requirements sign-off to UAT and AI-assisted impact assessment for amendments, but does not claim changes without downtime.
Native eCOA and third-party EDC connections are stated alongside RTSM APIs.
Extended support means: Integration with a clinical-trial application plus an API for integration are both stated.
The RTSM connects to Signant's own eCOA and supplies software, third-party EDC and manufacturing systems, and offers RTSM APIs for near real-time data.
Part 11 is stated for supply inventory history; ISO/SOC attestation evidence was not found.
Supported means: Relevant trial compliance or security controls are stated, with their scope identified.
Signant states that its SmartSignals Supplies inventory transaction history is 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation.
Product-specific study and customer adoption is reported across a stated country count.
Extended support means: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
A March 2026 Signant brochure reports 2,000+ RTSM studies in 90+ countries and 600+ sponsors and CROs as customers.
Adaptive and stratified randomization are stated; minimization or dynamic allocation is not named.
Supported means: Randomization or blinding workflows are stated.
Suvoda lists adaptive randomization, stratification, cohort and dose management and blinding management, but its public pages do not name minimization or dynamic allocation.
Drug forecasting and direct-to-patient shipping are both named.
Extended support means: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
The RTSM page lists drug supply forecasting, direct-to-patient shipping, temperature excursion management, and accountability, returns and destruction.
The UAT timeline concerns preliminary testing; permissioned changes do not establish uninterrupted live use.
Supported means: Study setup or post-go-live study changes are described.
Suvoda states kickoff to UAT in as little as two weeks (footnoted as preliminary testing), and permissioned users can make common post-go-live changes without a change order.
RTSM trial controls and an annual SOC audit are stated; public report access is not established.
Supported means: Relevant trial compliance or security controls are stated, with their scope identified.
Suvoda says its RTSM adheres to 21 CFR Part 11 and that it maintains SOC 2 Type 2 compliance; its certifications page confirms an annual SOC 2 Type 2 audit for RTSM.
Product-specific trial adoption is reported across a stated country count.
Extended support means: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Suvoda reports 6,000+ trials and 115+ countries supported.
Predictive resupply establishes base support; direct-to-patient shipping is not documented.
Supported means: Drug inventory, dispensing, shipping or resupply workflows are documented.
Veeva documents threshold, predictive and just-in-time resupply with expiry buffers and accountability, but no direct-to-patient shipping or separate forecasting tool.
Mid-study cohort and limit changes are stated; an initial build timeline and uninterrupted changes are not established.
Supported means: Study setup or post-go-live study changes are described.
Authorized users can switch on cohorts and change limits mid-study, and Veeva says design-change amendments often take days rather than weeks; no initial build timeline is published.
Native and external trial-system connections establish base support; an API is not stated in this note.
Supported means: Integration or data exchange with another system or application is described.
Productized connections send data to Veeva EDC, eCOA and DQS and take site data from Veeva CTMS, and the brief cites third-party EDC and shipping-provider connections.
An enterprise-standard selection provides base track-record evidence; product-specific adoption figures are not published.
Supported means: Published product or wider-platform adoption, or a named clinical-research deployment.
Veeva reports that a top-20 biopharma selected Veeva RTSM as its enterprise standard (fiscal 2026); no total study or customer count for RTSM is published.
Named methods include permuted blocks, dynamic allocation and minimization.
Extended support means: Named allocation methods include minimization or dynamic allocation.
YPrime names permuted block and stratified randomization, dynamic allocation and minimization (Pocock and Simon), stratum caps and conditional re-randomization.
Inventory and resupply establish base support; forecasting and direct-to-patient shipping are not described.
Supported means: Drug inventory, dispensing, shipping or resupply workflows are documented.
The IRT page covers inventory, orders, resupply, kit replacement and depot rules, but does not describe supply forecasting or direct-to-patient shipping.
Build timelines and immediately effective routine changes are stated; uninterrupted live use is not explicit.
Supported means: Study setup or post-go-live study changes are described.
YPrime cites build to go-live in under four weeks for an early-phase oncology trial, about a week for the simplest designs, and self-service routine changes that take effect immediately.
Every product uses the same definitions. Double checks indicate documented extra capabilities in that column; they do not indicate an overall winner. Unknown means the available sources do not establish support.
Randomization and blinding
Supported: Randomization or blinding workflows are stated.
Extended support: Named allocation methods include minimization or dynamic allocation.
Trial supply management
Supported: Drug inventory, dispensing, shipping or resupply workflows are documented.
Extended support: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Study build speed and mid-study changes
Supported: Study setup or post-go-live study changes are described.
Extended support: Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Integrations and platform
Supported: Integration or data exchange with another system or application is described.
Extended support: Integration with a clinical-trial application plus an API for integration are both stated.
Compliance and security evidence
Supported: Relevant trial compliance or security controls are stated, with their scope identified.
Extended support: Relevant trial controls and a publicly accessible ISO certificate or SOC audit report covering the product or vendor are documented.
Track record
Supported: Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Read the detailed feature comparison
Columns 6 of 6
Feature 1 of 6
Select a feature label for its details and source. Scroll sideways for all features.
Feature statements for each product, with public sources. Products appear in editorial order.
Stratification, variable blocks + minimization — details and source
4G names stratification, cohort-specific logic, variable blocks and minimization, with versioned logic that protects blinding and handles re-randomization.
Predictive resupply + modeling + direct-to-patient — details and source
Prancer handles dispensing and resupply with buffer-to-predictive forecasting and 4C Supply scenario modeling; direct-to-patient shipping was added in April 2020 (4G blog).
Under 4 weeks; changes protect progress (vendor claim) — details and source
4G says its NLP-based build takes under four weeks, with specification sign-off to go-live in as little as 13 calendar days, and changes made without impacting study progress.
EDC/CTMS/logistics links; no public API reference — details and source
4G documents connections to EDC, CTMS, depot and logistics systems and data warehouses, but has no EDC or eCOA of its own and we found no public API reference.
Resupply + SupplyWise forecasting + direct-to-patient — details and source
IXRS 3 documents resupply strategy, expiry and depot management, Almac's SupplyWise integrates demand forecasting with the IRT, and an Almac datasheet (Clinical Leader, August 2025) describes direct-to-patient workflows.
REST/SOAP/file links; no native EDC/eCOA — details and source
Almac lists pre-built connectors and REST, SOAP and secure file integrations with EDC, CTMS, clinical supplies and central labs, but has no EDC or eCOA of its own.
Training module Part 11 stated; ISO/SOC not found — details and source
Almac states its IXRS University training module is validated and 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation for Clinical Technologies.
Adaptive designs; allocation methods not named — details and source
Endpoint cites complex protocols, dosing strategies, adaptive designs and patient rollover, but its product pages do not name specific allocation methods.
API-based suite links; specific systems not named — details and source
Endpoint describes pre-built, API-based integrations with EDC, eCOA, eConsent and CTMS, but names no specific systems and has no EDC or eCOA of its own.
Block/dynamic allocation + simulator (2019 sheet) — details and source
A Medidata fact sheet lists pre-validated permuted block and dynamic allocation, stratification, cohort management, titration and a randomization simulator (fact sheet dated May 2019).
Predictive forecasting + direct-to-patient/pooling — details and source
The current fact sheet documents buffer and predictive supply schemes, forecasting that simulates future patient needs, direct-to-patient shipments and drug pooling across studies.
2–3 weeks; little/no downtime (vendor claim) — details and source
Medidata states a 2-3 week study build, and Edit Live Design allows post-go-live changes for protocol amendments (the 2024 fact sheet adds 'little to no downtime').
ISO/SOC listed; Part 11 statements behind login — details and source
Medidata lists an ISO 27001:2022 certificate and a SOC 2+ Type II audit, and says its position statements cover 21 CFR Part 11 and EU Annex 11 (the statements sit behind a customer login).
Direct-to-patient + pooling + forecasting — details and source
Signant documents direct-to-patient dispensing, cross-study pooling, shelf-life optimization and a Forecasting and Planning module in SmartSignals Supplies.
From 3 weeks to UAT (vendor claim); downtime not stated — details and source
Signant states new builds in as little as three weeks from requirements sign-off to UAT and AI-assisted impact assessment for amendments, but does not claim changes without downtime.
Native eCOA/supply + EDC links + RTSM APIs — details and source
The RTSM connects to Signant's own eCOA and supplies software, third-party EDC and manufacturing systems, and offers RTSM APIs for near real-time data.
Part 11 inventory history stated; ISO/SOC not found — details and source
Signant states that its SmartSignals Supplies inventory transaction history is 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation.
Adaptive/stratified randomization + cohort/dose rules — details and source
Suvoda lists adaptive randomization, stratification, cohort and dose management and blinding management, but its public pages do not name minimization or dynamic allocation.
Forecasting + direct-to-patient + temperature tracking — details and source
The RTSM page lists drug supply forecasting, direct-to-patient shipping, temperature excursion management, and accountability, returns and destruction.
UAT from 2 weeks (preliminary testing; vendor claim) — details and source
Suvoda states kickoff to UAT in as little as two weeks (footnoted as preliminary testing), and permissioned users can make common post-go-live changes without a change order.
Part 11 stated; annual RTSM SOC 2 Type 2 audit — details and source
Suvoda says its RTSM adheres to 21 CFR Part 11 and that it maintains SOC 2 Type 2 compliance; its certifications page confirms an annual SOC 2 Type 2 audit for RTSM.
Predictive/JIT resupply; direct-to-patient undocumented — details and source
Veeva documents threshold, predictive and just-in-time resupply with expiry buffers and accountability, but no direct-to-patient shipping or separate forecasting tool.
Cohort/limit changes; initial build time unpublished — details and source
Authorized users can switch on cohorts and change limits mid-study, and Veeva says design-change amendments often take days rather than weeks; no initial build timeline is published.
Native EDC/eCOA/DQS/CTMS + external links — details and source
Productized connections send data to Veeva EDC, eCOA and DQS and take site data from Veeva CTMS, and the brief cites third-party EDC and shipping-provider connections.
Enterprise client example; RTSM totals not published — details and source
Veeva reports that a top-20 biopharma selected Veeva RTSM as its enterprise standard (fiscal 2026); no total study or customer count for RTSM is published.
Permuted blocks, dynamic allocation + minimization — details and source
YPrime names permuted block and stratified randomization, dynamic allocation and minimization (Pocock and Simon), stratum caps and conditional re-randomization.
Resupply; forecasting/direct-to-patient not described — details and source
The IRT page covers inventory, orders, resupply, kit replacement and depot rules, but does not describe supply forecasting or direct-to-patient shipping.
Under 4 weeks in case study (vendor claim) — details and source
YPrime cites build to go-live in under four weeks for an early-phase oncology trial, about a week for the simplest designs, and self-service routine changes that take effect immediately.
No prices published; the Patient Cloud service descriptions publish contract terms (devices on a rental basis, caps on fee adjustments, early-termination fees)
Study fit: sponsors and CROs with complex dosing or adaptive designs who want an RTSM specialist with supply forecasting
4G Clinical is an RTSM specialist: Prancer covers randomization, resupply and direct-to-patient shipping, and 4C Supply adds portfolio-level forecasting. It publishes a SOC 2 Type 2 report and a Part 11 statement, and says it has supported more than 1,000 studies. It has no EDC or eCOA of its own, so plan for integrations.
Randomization and blinding
4G names stratification, cohort-specific logic, variable blocks and minimization, with versioned logic that protects blinding and handles re-randomization.
Prancer handles dispensing and resupply with buffer-to-predictive forecasting and 4C Supply scenario modeling; direct-to-patient shipping was added in April 2020 (4G blog).
4G says its NLP-based build takes under four weeks, with specification sign-off to go-live in as little as 13 calendar days, and changes made without impacting study progress.
4G documents connections to EDC, CTMS, depot and logistics systems and data warehouses, but has no EDC or eCOA of its own and we found no public API reference.
Study fit: sponsors who also use Almac for clinical packaging and distribution and want IRT, forecasting and logistics from one group
Almac's IXRS 3 links to Almac's own clinical supply, SupplyWise forecasting and distribution services, and supports direct-to-patient workflows. Almac reports about 2,000 trials run on IXRS. Its public pages give no build timeline, name few randomization methods and show no named security certification.
Randomization and blinding
Almac describes simple to complex adaptive designs with enrollment caps, cohorts and blinding protection, but does not name allocation methods.
IXRS 3 documents resupply strategy, expiry and depot management, Almac's SupplyWise integrates demand forecasting with the IRT, and an Almac datasheet (Clinical Leader, August 2025) describes direct-to-patient workflows.
Almac lists pre-built connectors and REST, SOAP and secure file integrations with EDC, CTMS, clinical supplies and central labs, but has no EDC or eCOA of its own.
Almac states its IXRS University training module is validated and 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation for Clinical Technologies.
Study fit: sponsors who want an RTSM specialist with self-service study changes and central pharmacy workflows
Endpoint Clinical is an RTSM specialist with two platforms: PULSE, with 20+ self-service modules, and the newer Elosity, which claims 2-6 week study setup and adds direct-to-patient shipping. Its Bluefin product adds supply forecasting. Public pages name few randomization methods, and the only named attestation is SOC 2 Type II.
Randomization and blinding
Endpoint cites complex protocols, dosing strategies, adaptive designs and patient rollover, but its product pages do not name specific allocation methods.
Endpoint describes pre-built, API-based integrations with EDC, eCOA, eConsent and CTMS, but names no specific systems and has no EDC or eCOA of its own.
Study fit: sponsors already on Rave EDC who want randomization and supply in the same system
Medidata RTSM is unified with Rave EDC, so randomization and dispensing data do not need reconciling between two systems. Its fact sheets document block, stratified and dynamic allocation, supply forecasting, direct-to-patient shipping and post-go-live changes with little to no downtime. Pricing is not published.
Randomization and blinding
A Medidata fact sheet lists pre-validated permuted block and dynamic allocation, stratification, cohort management, titration and a randomization simulator (fact sheet dated May 2019).
The current fact sheet documents buffer and predictive supply schemes, forecasting that simulates future patient needs, direct-to-patient shipments and drug pooling across studies.
Medidata states a 2-3 week study build, and Edit Live Design allows post-go-live changes for protocol amendments (the 2024 fact sheet adds 'little to no downtime').
Medidata lists an ISO 27001:2022 certificate and a SOC 2+ Type II audit, and says its position statements cover 21 CFR Part 11 and EU Annex 11 (the statements sit behind a customer login).
No prices published; the Patient Cloud service descriptions publish contract terms (devices on a rental basis, caps on fee adjustments, early-termination fees)Source
Security certifications
ISO 27001:2022, ISO 27017:2015, ISO 27018:2019, ISO 27701:2019, SOC 2+ Type IISource
Headquarters
New York, NY (350 Hudson Street, per ISO certificate)Source
Less suitable for teams that need published prices or a self-serve contract for a single small study.
Study fit: sponsors who want RTSM, supply forecasting and eCOA from one vendor
Signant's RTSM sits next to its SmartSignals Supplies forecasting and inventory software and its eCOA, with direct-to-patient dispensing and pooling across studies. Signant reports 2,000+ RTSM studies and builds in as little as three weeks to UAT. Its public RTSM pages do not name randomization methods or a security certification.
Randomization and blinding
Signant mentions emergency unblinding and support for any protocol design or randomization scheme, but does not name allocation methods.
Signant documents direct-to-patient dispensing, cross-study pooling, shelf-life optimization and a Forecasting and Planning module in SmartSignals Supplies.
Signant states new builds in as little as three weeks from requirements sign-off to UAT and AI-assisted impact assessment for amendments, but does not claim changes without downtime.
The RTSM connects to Signant's own eCOA and supplies software, third-party EDC and manufacturing systems, and offers RTSM APIs for near real-time data.
Signant states that its SmartSignals Supplies inventory transaction history is 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation.
Study fit: oncology, CNS and rare disease sponsors who want IRT alongside eCOA, eConsent and patient payments on one platform
Suvoda runs its RTSM on one platform with eCOA, eConsent and Greenphire patient payments, and offers pre-built API integrations with major EDCs. It publishes the shortest build claim on this list (kickoff to UAT in as little as two weeks, footnoted as preliminary testing) and an annual SOC 2 Type 2 audit for RTSM. Its public pages name stratification and adaptive designs but not minimization.
Randomization and blinding
Suvoda lists adaptive randomization, stratification, cohort and dose management and blinding management, but its public pages do not name minimization or dynamic allocation.
The RTSM page lists drug supply forecasting, direct-to-patient shipping, temperature excursion management, and accountability, returns and destruction.
Suvoda states kickoff to UAT in as little as two weeks (footnoted as preliminary testing), and permissioned users can make common post-go-live changes without a change order.
Suvoda says its RTSM adheres to 21 CFR Part 11 and that it maintains SOC 2 Type 2 compliance; its certifications page confirms an annual SOC 2 Type 2 audit for RTSM.
Study fit: sponsors standardizing on the Veeva Clinical Platform who want RTSM connected to Veeva EDC, eCOA and CTMS
Veeva RTSM lists a broad set of randomization schemas and productized connections to Veeva EDC, eCOA and CTMS, and a top-20 biopharma chose it as its enterprise standard in fiscal 2026. Public material does not describe direct-to-patient shipping or a dedicated forecasting tool, and no build timeline is published.
Randomization and blinding
Veeva lists static, stratified, dynamic/minimization, forced and adaptive schemas, re-randomization, capping and sentinel dosing.
Veeva documents threshold, predictive and just-in-time resupply with expiry buffers and accountability, but no direct-to-patient shipping or separate forecasting tool.
Authorized users can switch on cohorts and change limits mid-study, and Veeva says design-change amendments often take days rather than weeks; no initial build timeline is published.
Productized connections send data to Veeva EDC, eCOA and DQS and take site data from Veeva CTMS, and the brief cites third-party EDC and shipping-provider connections.
Veeva reports that a top-20 biopharma selected Veeva RTSM as its enterprise standard (fiscal 2026); no total study or customer count for RTSM is published.
Study fit: sponsors with complex randomization schemes, including minimization, who may also use YPrime eCOA
YPrime names more randomization methods than any other vendor here, from permuted blocks to Pocock-Simon minimization, and publishes short build times. Its public IRT page does not describe supply forecasting or direct-to-patient shipping, and we found no named security certification.
Randomization and blinding
YPrime names permuted block and stratified randomization, dynamic allocation and minimization (Pocock and Simon), stratum caps and conditional re-randomization.
The IRT page covers inventory, orders, resupply, kit replacement and depot rules, but does not describe supply forecasting or direct-to-patient shipping.
YPrime cites build to go-live in under four weeks for an early-phase oncology trial, about a week for the simplest designs, and self-service routine changes that take effect immediately.
This guide compares 8 products across the same feature topics. Each statement describes what the available public sources document, including limitations and study requirements.
Scope: Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.
Randomization and blinding
Trial supply management
Study build speed and mid-study changes
Integrations and platform
Compliance and security evidence
Track record
A vendor’s published claim is not independent confirmation that a product will meet your study’s needs. Check deployment, validation, integrations and commercial terms with the vendor.
Outside this comparison: Calyx (calyx.ai now redirects to perceptive.com) and IQVIA's Cenduit IRT were considered but not included in this comparison; this comparison covers eight vendors with public documentation available for review.
They describe the same kind of system. IRT (interactive response technology) is the older name, from phone and web randomization systems; RTSM (randomization and trial supply management) names what the system does: assign participants to treatment and keep sites or patients supplied with blinded study drug.
How long does it take to build an RTSM study?
Vendors on this list publish build claims of roughly two to six weeks: Suvoda says kickoff to UAT in as little as two weeks (preliminary testing), Medidata a 2-3 week build, Signant about three weeks to UAT, 4G Clinical under four weeks and Endpoint's Elosity 2-6 weeks. These are vendor figures, so ask for timelines on studies like yours.
Which RTSM systems support direct-to-patient shipping?
Medidata, 4G Clinical, Suvoda, Endpoint (Elosity), Signant and Almac publicly document direct-to-patient shipping. The public RTSM pages of YPrime and Veeva do not describe it, so confirm it in a demo if your study needs it.
How much does an RTSM system cost?
None of the eight vendors publishes prices. Large sponsors often buy RTSM study by study, as Veeva noted in its fiscal 2026 results call. Ask for a quote that separates the initial build, monthly hosting and the cost of mid-study changes.